**Improving iron supplements: cooking with GOS**

Hal Drakesmith1\* and Stephen J. Allen2

*Commentary* on ‘Prebiotic galacto-oligosaccharides mitigate the adverse effects of iron fortification on the gut microbiome: a randomized controlled study in Kenyan infants’ by Paganini *et al*

1) MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital and University of Oxford, Oxford OX3 9DS, UK

2) Department of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK

\*Corresponding author: Hal Drakesmith

email: [alexander.drakesmith@ndm.ox.ac.uk](mailto:alexander.drakesmith@ndm.ox.ac.uk)

tel: +44 1865 222699

fax: +44 1865 222406

Keywords: Iron absorption, infant/neonatal nutrition, inflammation, infectious disease, prebiotic

Abbreviations: MNPs: multiple micronutrient powders

GOS: galacto-oligosaccharides

GRAS: Generally Regarded as Safe

Fe-MNPs: MNPs with 5mg Fe

FeGOS: MNPs with 5mg Fe and with 7.5g GOS

RTI: respiratory tract infection

Word count: 1003

Iron is essential for oxygen transport, generation of energy, synthesis of DNA and multiple enzymatic systems. Iron deficiency impairs these functions and a familiar and important manifestation of advanced iron deficiency is anaemia. Around a quarter of a billion children worldwide are anaemic, and at least half of childhood anaemia is caused in part by a lack of iron; a heavy burden of anaemia is especially present in sub-Saharan Africa and South Asia[1]. Iron replenishments, including iron-containing multiple micronutrient powders (MNPs) can be effective treatments to increase haemoglobin. However, despite the use of such agents for many years, the estimated prevalence of anaemia worldwide in pre-school children only decreased from 47% to 43% between 1993 and 2011[2]. Furthermore, iron replenishments have been associated with adverse events, including infections, intestinal inflammation and diarrhea, in some (but not all) trials. There is a need to make iron treatments both safer and more effective especially in the developing world, and the study in Kenya by Zimmermann and colleagues[3] in this issue of *Gut* addresses these issues.

Iron is needed for growth not only by humans, but also by microbes that colonize and infect us. In particular, pathogenic bacteria in the gut require iron for their virulence, while conversely beneficial microbes include *Lactobacilli* that are a rare example of life that does not use iron to grow[4]. Previous work by the Zimmermann group has shown that iron-containing MNPs can favour the outgrowth of harmful enteropathogens at the expense of protective *Bifidobacteriaceae* and *Lactobacillaceae*, and increase intestinal inflammation in some children[5]; and a trial of MNPs containing iron in Pakistan found an increased level of diarrhea (including bloody-diarrhea)[6]. Additionally, there is strong evidence that iron can exacerbate the risk of malaria in children[7], so that in malarial-endemic areas, anti-malarial measures must be implemented alongside iron supplementation[8].

The Zimmermann group engineered a new formulation of iron-containing MNPs in an attempt to reduce intestinal morbidities while sustaining the beneficial effects of iron. First, they lowered the dose of iron from 12.5mg to 5mg; second, half of this iron was given in a chelated highly-bioavailable form (NaFeEDTA); third, they included a prebiotic of galacto-oligosaccharides (GOS) that can selectively enhance growth of *Bifidobacteriaceae* and *Lactobacillaceae[9].* GOS has GRAS status (Generally Recognized as Safe – FDA designation) and is frequently added to infant formula milk in industrialized countries.

To test the new formulation, 155 infants aged 6.5–9.5 months were recruited, all of whom had had no vitamin and mineral supplements in the previous 8 weeks, no antibiotic treatments in the previous 10 weeks, and had anticipated residence in the study area, in southern coastal Kenya, for the four-month protocol[3]. Children were randomly assigned to one of three groups; children within each group received daily either MNPs without iron (control), or MNPs with 5mg Fe (Fe-MNPs), or MNPs with 5mg iron and with 7.5g GOS (FeGOS; Trial Registration Number: NCT02118402). At the end of four months, anaemia decreased by about half in both of the groups receiving iron compared to control, indicating the GOS had not interfered with the ability to MNPs containing iron to increase haemoglobin levels. In terms of the microbiota, fecal material was used and ~23000 bacterial 16S rDNA sequences per sample were analysed, along with qPCR measurement of specific genes from selected enteropathogenic bacterial species. The results showed that compared to both the control and the FeGOS groups, children receiving Fe-MNPs had lower abundances of protective *Bifidobacterium* and *Lactobacillus*, higher abundances of *Clostridiales* and of virulence and toxin genes of pathogens, plus higher plasma levels of intestinal fatty acid binding protein, indicating increased damage to enterocytes. Notably, there were no significant differences in these measures between FeGOS and control groups.

Intriguingly, a higher incidence of treated respiratory tract infections (RTIs) occurred in the Fe-MNP group compared to either the control or FeGOS groups. Neither the increase in RTIs with iron nor the ameliorative effect of GOS are straightforward to explain, but the former result is consistent with a previous study suggesting increased evidence of RTIs in children receiving iron-MNPs[6]. Interestingly, the fecal microbiota has also been linked to important respiratory infections in pigs[10]. The protective effects of GOS on the gut microbiota may have wider positive implications for systemic immunity that could decrease RTIs. This raises two further issues: firstly, what is the effect of GOS on iron-associated susceptibility to other infections in children, especially malaria? Second, oral iron replenishment can be ineffective due to blockade of iron absorption by the master iron regulatory hormone hepcidin, which is upregulated by infection and inflammation[11]; so what is the effect of GOS on hepcidin and on the efficiency of dietary iron uptake?

Overall, these important results indicate that GOS may be able to counteract the adverse effect of iron on the infant gut microbiota observed in this and previous studies, while maintaining efficacy against anaemia at a relatively low dose of iron. As such the data deserve significant attention. Future studies are needed to understand and further evaluate the effects and utility of GOS. For example, gut microbiota composition appears to be particularly labile and vulnerable in early life[12], so are the beneficial effects of GOS restricted to infants or would there also be benefit to their use in older children? What are the minimum doses of iron and GOS that together have both haematological and microbiota benefits? Would children in other developing countries or regions, for example South Asia, also experience beneficial effects of GOS? How does the gut microbiota develop over longer time periods after infant exposure to GOS, and are there wider effects of GOS on uptake of other nutrients besides iron?

A broader point is this study illustrates that nutritional interventions for specific indications (here, iron for anaemia) may cause unexpected collateral damage (here, stimulation of gut pathogen growth, increased RTIs) that require countermeasures. This highlights the need for awareness of effects beyond the main outcomes in intervention studies – while this need is demonstrably important in the context of iron, it may also be relevant for other nutrients.

**References**

1 Kassebaum NJ, Collaborators GBDA. The Global Burden of Anemia. Hematol Oncol Clin North Am 2016;**30**:247-308.

2 Stevens GA, Finucane MM, De-Regil LM, Paciorek CJ, Flaxman SR, Branca F*, et al.* Global, regional, and national trends in haemoglobin concentration and prevalence of total and severe anaemia in children and pregnant and non-pregnant women for 1995-2011: a systematic analysis of population-representative data. The Lancet Global Health 2013;**1**:e16-e25.

3 Paganini D, Uyoga MA, Kortman GA, Cercamondi CI, Moretti D, Barth-Jaeggi T*, et al.* Prebiotic galacto-oligosaccharides mitigate the adverse effects of iron fortification on the gut microbiome: a randomized controlled study in Kenyan infants. Gut 2017.

4 Weinberg ED. The Lactobacillus anomaly: total iron abstinence. Perspectives in biology and medicine 1997;**40**:578-83.

5 Jaeggi T, Kortman GA, Moretti D, Chassard C, Holding P, Dostal A*, et al.* Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants. Gut 2015;**64**:731-42.

6 Soofi S, Cousens S, Iqbal SP, Akhund T, Khan J, Ahmed I*, et al.* Effect of provision of daily zinc and iron with several micronutrients on growth and morbidity among young children in Pakistan: a cluster-randomised trial. Lancet 2013.

7 Sazawal S, Black RE, Ramsan M, Chwaya HM, Stoltzfus RJ, Dutta A*, et al.* Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial. Lancet 2006;**367**:133-43.

8 WHO. WHO guideline: Use of multiple micronutrient powders for point-of-use fortication of foods consumed by infants and young children aged 6–23 months and children aged 2–12 years. Geneva: World Health Organization, 2016.

9 Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ*, et al.* Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nature reviews Gastroenterology & hepatology 2017.

10 Niederwerder MC. Role of the microbiome in swine respiratory disease. Veterinary microbiology 2017.

11 Prentice AM, Doherty CP, Abrams SA, Cox SE, Atkinson SH, Verhoef H*, et al.* Hepcidin is the major predictor of erythrocyte iron incorporation in anemic African children. Blood 2012;**119**:1922-8.

12 Arrieta MC, Stiemsma LT, Amenyogbe N, Brown EM, Finlay B. The intestinal microbiome in early life: health and disease. Frontiers in immunology 2014;**5**:427.

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in Gut editions and any other BMJPGL products to exploit all subsidiary rights, as set out in our licence ([http://group.bmj.com/products/journals/instructions-for-authors/licence-forms).](https://owa.nexus.ox.ac.uk/owa/redir.aspx?SURL=QnRzdv2qOZukjXJVGvQZ40VWpUJD9YVMIntUcewp0rvGjEKxFsPUCGgAdAB0AHAAOgAvAC8AZwByAG8AdQBwAC4AYgBtAGoALgBjAG8AbQAvAHAAcgBvAGQAdQBjAHQAcwAvAGoAbwB1AHIAbgBhAGwAcwAvAGkAbgBzAHQAcgB1AGMAdABpAG8AbgBzAC0AZgBvAHIALQBhAHUAdABoAG8AcgBzAC8AbABpAGMAZQBuAGMAZQAtAGYAbwByAG0AcwApAC4A&URL=http%3a%2f%2fgroup.bmj.com%2fproducts%2fjournals%2finstructions-for-authors%2flicence-forms).)

Competing Interest: None declared